{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:20:06Z","timestamp":1790400006487,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T00:00:00Z","timestamp":1663113600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T00:00:00Z","timestamp":1663113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["EXC 2145 SyNergy \u2013 ID 390857198"],"award-info":[{"award-number":["EXC 2145 SyNergy \u2013 ID 390857198"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SCHR 774\/5-1"],"award-info":[{"award-number":["SCHR 774\/5-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["01EK1605A HitTau"],"award-info":[{"award-number":["01EK1605A HitTau"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e4tsklinik M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract\n<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Early after [<jats:sup>18<\/jats:sup>F]PI-2620 PET tracer administration, perfusion imaging has potential for regional assessment of neuronal injury in neurodegenerative diseases. This is while standard late-phase [<jats:sup>18<\/jats:sup>F]PI-2620 tau-PET is able to discriminate the 4-repeat tauopathies progressive supranuclear palsy and corticobasal syndrome (4RTs) from disease controls and healthy controls. Here, we investigated whether early-phase [<jats:sup>18<\/jats:sup>F]PI-2620 PET has an additive value for biomarker based evaluation of 4RTs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Seventy-eight patients with 4RTs (71\u2009\u00b1\u20097\u00a0years, 39 female), 79 patients with other neurodegenerative diseases (67\u2009\u00b1\u200912\u00a0years, 35 female) and twelve age-matched controls (69\u2009\u00b1\u20098\u00a0years, 8 female) underwent dynamic (0\u201360\u00a0min) [<jats:sup>18<\/jats:sup>F]PI-2620 PET imaging. Regional perfusion (0.5\u20132.5\u00a0min p.i.) and tau load (20\u201340\u00a0min p.i.) were measured in 246 predefined brain regions [standardized-uptake-value ratios (SUVr), cerebellar reference]. Regional SUVr were compared between 4RTs and controls by an ANOVA including false-discovery-rate (FDR, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01) correction. Hypoperfusion in resulting 4RT target regions was evaluated at the patient level in all patients (mean value\u2009\u2212\u20092SD threshold). Additionally, perfusion and tau pattern expression levels were explored regarding their potential discriminatory value of 4RTs against other neurodegenerative disorders, including validation in an independent external dataset (<jats:italic>n<\/jats:italic>\u2009=\u200937), and correlated with clinical severity in 4RTs (PSP rating scale, MoCA, activities of daily living).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Patients with 4RTs had significant hypoperfusion in 21\/246 brain regions, most dominant in thalamus, caudate nucleus, and anterior cingulate cortex, fitting to the topology of the 4RT disease spectrum. However, single region hypoperfusion was not specific regarding the discrimination of patients with 4RTs against patients with other neurodegenerative diseases. In contrast, perfusion pattern expression showed promise for discrimination of patients with 4RTs from other neurodegenerative diseases (AUC: 0.850). Discrimination by the combined perfusion-tau pattern expression (AUC: 0.903) exceeded that of the sole tau pattern expression (AUC: 0.864) and the discriminatory power of the combined perfusion-tau pattern expression was replicated in the external dataset (AUC: 0.917). Perfusion but not tau pattern expression was associated with PSP rating scale (<jats:italic>R<\/jats:italic>\u2009=\u20090.402; <jats:italic>p<\/jats:italic>\u2009=\u20090.0012) and activities of daily living (<jats:italic>R<\/jats:italic>\u2009=\u2009\u2009\u2212\u20090.431; <jats:italic>p<\/jats:italic>\u2009=\u20090.0005).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>[<jats:sup>18<\/jats:sup>F]PI-2620 perfusion imaging mirrors known topology of regional hypoperfusion in 4RTs. Single region hypoperfusion is not specific for 4RTs, but perfusion pattern expression may provide an additive value for the discrimination of 4RTs from other neurodegenerative diseases and correlates closer with clinical severity than tau pattern expression.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00259-022-05964-w","type":"journal-article","created":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T05:03:27Z","timestamp":1663131807000},"page":"423-434","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Additive value of [18F]PI-2620 perfusion imaging in progressive supranuclear palsy and corticobasal syndrome"],"prefix":"10.1007","volume":"50","author":[{"given":"Sabrina","family":"Katzdobler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Nitschmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henryk","family":"Barthel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Bischof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonie","family":"Beyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Marek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengmeng","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Wagemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Palleis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Endy","family":"Weidinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Nack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urban","family":"Fietzek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Kurz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"H\u00e4ckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Stapf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Ferschmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Scheifele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Eckenweber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Biechele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolai","family":"Franzmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Dewenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Sch\u00f6necker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothee","family":"Saur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias L.","family":"Schroeter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jost-Julian","family":"Rumpf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Rullmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schildan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Patt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew W.","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thilo","family":"van Eimeren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Neumaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Drzezga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Danek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Classen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"B\u00fcrger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Janowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris-Stephan","family":"Rauchmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"St\u00f6cklein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Perneczky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Sch\u00f6berl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Zwergal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter U.","family":"H\u00f6glinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bartenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Villemagne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Seibyl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Sabri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9247-2843","authenticated-orcid":false,"given":"Matthias","family":"Brendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the German Imaging Initiative for Tauopathies (GII4T)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,14]]},"reference":[{"key":"5964_CR1","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1001\/jamaneurol.2020.2526","volume":"77","author":"M Brendel","year":"2020","unstructured":"Brendel M, Barthel H, van Eimeren T, Marek K, Beyer L, Song M, et al. Assessment of 18F-PI-2620 as a biomarker in progressive supranuclear palsy. JAMA Neurol. 2020;77:1408\u201319. https:\/\/doi.org\/10.1001\/jamaneurol.2020.2526.","journal-title":"JAMA Neurol"},{"key":"5964_CR2","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1002\/mds.28624","volume":"36","author":"C Palleis","year":"2021","unstructured":"Palleis C, Brendel M, Finze A, Weidinger E, Botzel K, Danek A, et al. Cortical [(18) F]PI-2620 binding differentiates corticobasal syndrome subtypes. Mov Disord. 2021;36:2104\u201315. https:\/\/doi.org\/10.1002\/mds.28624.","journal-title":"Mov Disord"},{"issue":"42\u201358","key":"5964_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2020.09.042","volume":"109","author":"K Tagai","year":"2021","unstructured":"Tagai K, Ono M, Kubota M, Kitamura S, Takahata K, Seki C, et al. High-contrast in vivo imaging of tau pathologies in Alzheimer\u2019s and non-Alzheimer\u2019s disease tauopathies. Neuron. 2021;109(42\u201358): e8. https:\/\/doi.org\/10.1016\/j.neuron.2020.09.042.","journal-title":"Neuron"},{"key":"5964_CR4","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.brainresbull.2016.08.018","volume":"126","author":"T Arendt","year":"2016","unstructured":"Arendt T, Stieler JT, Holzer M. Tau and tauopathies. Brain Res Bull. 2016;126:238\u201392. https:\/\/doi.org\/10.1016\/j.brainresbull.2016.08.018.","journal-title":"Brain Res Bull"},{"key":"5964_CR5","doi-asserted-by":"publisher","first-page":"101644","DOI":"10.1016\/j.pneurobio.2019.101644","volume":"180","author":"TW Rosler","year":"2019","unstructured":"Rosler TW, TayaranianMarvian A, Brendel M, Nykanen NP, Hollerhage M, Schwarz SC, et al. Four-repeat tauopathies. Prog Neurobiol. 2019;180:101644. https:\/\/doi.org\/10.1016\/j.pneurobio.2019.101644.","journal-title":"Prog Neurobiol"},{"key":"5964_CR6","doi-asserted-by":"publisher","first-page":"e1121","DOI":"10.1212\/WNL.0000000000007038","volume":"92","author":"M Pardini","year":"2019","unstructured":"Pardini M, Huey ED, Spina S, Kreisl WC, Morbelli S, Wassermann EM, et al. FDG-PET patterns associated with underlying pathology in corticobasal syndrome. Neurology. 2019;92:e1121\u201335. https:\/\/doi.org\/10.1212\/WNL.0000000000007038.","journal-title":"Neurology"},{"key":"5964_CR7","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.3233\/JAD-190220","volume":"70","author":"M Khosravi","year":"2019","unstructured":"Khosravi M, Peter J, Wintering NA, Serruya M, Shamchi SP, Werner TJ, et al. 18F-FDG is a superior indicator of cognitive performance compared to 18F-florbetapir in Alzheimer\u2019s disease and mild cognitive impairment evaluation: a global quantitative analysis. J Alzheimers Dis. 2019;70:1197\u2013207. https:\/\/doi.org\/10.3233\/JAD-190220.","journal-title":"J Alzheimers Dis"},{"key":"5964_CR8","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1212\/wnl.0000000000002923","volume":"87","author":"CR Jack Jr","year":"2016","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, et al. A\/T\/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87:539\u201347. https:\/\/doi.org\/10.1212\/wnl.0000000000002923.","journal-title":"Neurology"},{"key":"5964_CR9","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/mds.26987","volume":"32","author":"GU Hoglinger","year":"2017","unstructured":"Hoglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord. 2017;32:853\u201364. https:\/\/doi.org\/10.1002\/mds.26987.","journal-title":"Mov Disord"},{"key":"5964_CR10","doi-asserted-by":"publisher","first-page":"661284","DOI":"10.3389\/fnagi.2021.661284","volume":"13","author":"J Schmitt","year":"2021","unstructured":"Schmitt J, Palleis C, Sauerbeck J, Unterrainer M, Harris S, Prix C, et al. Dual-phase \u03b2-amyloid PET captures neuronal injury and amyloidosis in corticobasal syndrome. Front Aging Neurosci. 2021;13:661284. https:\/\/doi.org\/10.3389\/fnagi.2021.661284.","journal-title":"Front Aging Neurosci"},{"key":"5964_CR11","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1007\/s00259-020-04788-w","volume":"47","author":"L Beyer","year":"2020","unstructured":"Beyer L, Nitschmann A, Barthel H, van Eimeren T, Unterrainer M, Sauerbeck J, et al. Early-phase [(18)F]PI-2620 tau-PET imaging as a surrogate marker of neuronal injury. Eur J Nucl Med Mol Imaging. 2020;47:2911\u201322. https:\/\/doi.org\/10.1007\/s00259-020-04788-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5964_CR12","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.dadm.2019.01.011","volume":"11","author":"T van Eimeren","year":"2019","unstructured":"van Eimeren T, Antonini A, Berg D, Bohnen N, Ceravolo R, Drzezga A, et al. Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: proposal for a Neuroimaging Biomarker Utility System. Alzheimers Dement (Amst). 2019;11:301\u20139. https:\/\/doi.org\/10.1016\/j.dadm.2019.01.011.","journal-title":"Alzheimers Dement (Amst)"},{"key":"5964_CR13","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1212\/WNL.0b013e31827f0fd1","volume":"80","author":"MJ Armstrong","year":"2013","unstructured":"Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80:496\u2013503. https:\/\/doi.org\/10.1212\/WNL.0b013e31827f0fd1.","journal-title":"Neurology"},{"key":"5964_CR14","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.jalz.2015.05.001","volume":"11","author":"WJ Jagust","year":"2015","unstructured":"Jagust WJ, Landau SM, Koeppe RA, Reiman EM, Chen K, Mathis CA, et al. The Alzheimer\u2019s disease neuroimaging initiative 2 PET core: 2015. Alzheimers Dement. 2015;11:757\u201371. https:\/\/doi.org\/10.1016\/j.jalz.2015.05.001.","journal-title":"Alzheimers Dement"},{"key":"5964_CR15","doi-asserted-by":"publisher","first-page":"3872","DOI":"10.1007\/s00259-021-05391-3","volume":"48","author":"M Song","year":"2021","unstructured":"Song M, Scheifele M, Barthel H, van Eimeren T, Beyer L, Marek K, et al. Feasibility of short imaging protocols for [(18)F]PI-2620 tau-PET in progressive supranuclear palsy. Eur J Nucl Med Mol Imaging. 2021;48:3872\u201385. https:\/\/doi.org\/10.1007\/s00259-021-05391-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5964_CR16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.nicl.2016.10.005","volume":"14","author":"S Daerr","year":"2017","unstructured":"Daerr S, Brendel M, Zach C, Mille E, Schilling D, Zacherl MJ, et al. Evaluation of early-phase [(18)F]-florbetaben PET acquisition in clinical routine cases. Neuroimage Clin. 2017;14:77\u201386. https:\/\/doi.org\/10.1016\/j.nicl.2016.10.005.","journal-title":"Neuroimage Clin"},{"key":"5964_CR17","doi-asserted-by":"publisher","first-page":"3508","DOI":"10.1093\/cercor\/bhw157","volume":"26","author":"L Fan","year":"2016","unstructured":"Fan L, Li H, Zhuo J, Zhang Y, Wang J, Chen L, et al. The Human Brainnetome Atlas: a new brain atlas based on connectional architecture. Cereb Cortex. 2016;26:3508\u201326. https:\/\/doi.org\/10.1093\/cercor\/bhw157.","journal-title":"Cereb Cortex"},{"key":"5964_CR18","first-page":"904","volume":"39","author":"OG Rousset","year":"1998","unstructured":"Rousset OG, Ma Y, Evans AC. Correction for partial volume effects in PET: principle and validation. J Nucl Med. 1998;39:904\u201311.","journal-title":"J Nucl Med"},{"key":"5964_CR19","doi-asserted-by":"publisher","first-page":"7975","DOI":"10.1088\/0031-9155\/61\/22\/7975","volume":"61","author":"BA Thomas","year":"2016","unstructured":"Thomas BA, Cuplov V, Bousse A, Mendes A, Thielemans K, Hutton BF, et al. PETPVC: a toolbox for performing partial volume correction techniques in positron emission tomography. Phys Med Biol. 2016;61:7975\u201393. https:\/\/doi.org\/10.1088\/0031-9155\/61\/22\/7975.","journal-title":"Phys Med Biol"},{"key":"5964_CR20","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/j.neuroimage.2008.12.063","volume":"45","author":"PG Spetsieris","year":"2009","unstructured":"Spetsieris PG, Ma Y, Dhawan V, Eidelberg D. Differential diagnosis of parkinsonian syndromes using PCA-based functional imaging features. Neuroimage. 2009;45:1241\u201352. https:\/\/doi.org\/10.1016\/j.neuroimage.2008.12.063.","journal-title":"Neuroimage"},{"key":"5964_CR21","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/ana.24885","volume":"81","author":"EG Spinelli","year":"2017","unstructured":"Spinelli EG, Mandelli ML, Miller ZA, Santos-Santos MA, Wilson SM, Agosta F, et al. Typical and atypical pathology in primary progressive aphasia variants. Ann Neurol. 2017;81:430\u201343. https:\/\/doi.org\/10.1002\/ana.24885.","journal-title":"Ann Neurol"},{"key":"5964_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28373","author":"JB Parmera","year":"2020","unstructured":"Parmera JB, Coutinho AM, Aranha MR, Studart-Neto A, de Godoi CC, de Almeida IJ, et al. FDG-PET patterns predict amyloid deposition and clinical profile in corticobasal syndrome. Mov Disord. 2020. https:\/\/doi.org\/10.1002\/mds.28373.","journal-title":"Mov Disord"},{"key":"5964_CR23","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1007\/s00259-018-4031-2","volume":"45","author":"Z Walker","year":"2018","unstructured":"Walker Z, Gandolfo F, Orini S, Garibotto V, Agosta F, Arbizu J, et al. Clinical utility of FDG PET in Parkinson\u2019s disease and atypical parkinsonism associated with dementia. Eur J Nucl Med Mol Imaging. 2018;45:1534\u201345. https:\/\/doi.org\/10.1007\/s00259-018-4031-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"5964_CR24","doi-asserted-by":"publisher","first-page":"627","DOI":"10.3233\/JAD-2011-110458","volume":"26","author":"LM Bloudek","year":"2011","unstructured":"Bloudek LM, Spackman DE, Blankenburg M, Sullivan SD. Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer\u2019s disease. J Alzheimers Dis. 2011;26:627\u201345. https:\/\/doi.org\/10.3233\/JAD-2011-110458.","journal-title":"J Alzheimers Dis"},{"key":"5964_CR25","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S1474-4422(10)70002-8","volume":"9","author":"CC Tang","year":"2010","unstructured":"Tang CC, Poston KL, Eckert T, Feigin A, Frucht S, Gudesblatt M, et al. Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. The Lancet Neurology. 2010;9:149\u201358. https:\/\/doi.org\/10.1016\/S1474-4422(10)70002-8.","journal-title":"The Lancet Neurology"},{"key":"5964_CR26","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1093\/brain\/awu256","volume":"137","author":"M Niethammer","year":"2014","unstructured":"Niethammer M, Tang CC, Feigin A, Allen PJ, Heinen L, Hellwig S, et al. A disease-specific metabolic brain network associated with corticobasal degeneration. Brain. 2014;137:3036\u201346. https:\/\/doi.org\/10.1093\/brain\/awu256.","journal-title":"Brain"},{"key":"5964_CR27","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/mds.21933","volume":"23","author":"T Eckert","year":"2008","unstructured":"Eckert T, Tang C, Ma Y, Brown N, Lin T, Frucht S, et al. Abnormal metabolic networks in atypical parkinsonism. Mov Disord. 2008;23:727\u201333. https:\/\/doi.org\/10.1002\/mds.21933.","journal-title":"Mov Disord"},{"key":"5964_CR28","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/mdc3.12582","volume":"5","author":"GU H\u00f6glinger","year":"2018","unstructured":"H\u00f6glinger GU. Is it useful to classify progressive supranuclear palsy and corticobasal degeneration as different disorders? No Movement disorders clinical practice. 2018;5:141.","journal-title":"No Movement disorders clinical practice"},{"key":"5964_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2019.101722","volume":"22","author":"F Albrecht","year":"2019","unstructured":"Albrecht F, Bisenius S, Neumann J, Whitwell J, Schroeter ML. Atrophy in midbrain & cerebral\/cerebellar pedunculi is characteristic for progressive supranuclear palsy - A double-validation whole-brain meta-analysis. Neuroimage Clin. 2019;22: 101722. https:\/\/doi.org\/10.1016\/j.nicl.2019.101722.","journal-title":"Neuroimage Clin"},{"key":"5964_CR30","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.257345","author":"S Peng","year":"2021","unstructured":"Peng S, Tang C, Schindlbeck K, Rydzinski Y, Dhawan V, Spetsieris PG, et al. Dynamic (18)F-FPCIT PET: Quantification of Parkinson\u2019s disease metabolic networks and nigrostriatal dopaminergic dysfunction in a single imaging session. J Nucl Med. 2021. https:\/\/doi.org\/10.2967\/jnumed.120.257345.","journal-title":"J Nucl Med"},{"key":"5964_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.684523","volume":"12","author":"M Willroider","year":"2021","unstructured":"Willroider M, Roeber S, Horn AKE, Arzberger T, Scheifele M, Respondek G, et al. Superiority of formalin-fixed paraffin-embedded brain tissue for in vitro assessment of progressive supranuclear palsy tau pathology with [(18) F]PI-2620. Front Neurol. 2021;12: 684523. https:\/\/doi.org\/10.3389\/fneur.2021.684523.","journal-title":"Front Neurol"},{"key":"5964_CR32","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14:535\u201362. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018.","journal-title":"Alzheimers Dement"},{"key":"5964_CR33","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.2967\/jnumed.112.113654","volume":"54","author":"BN van Berckel","year":"2013","unstructured":"van Berckel BN, Ossenkoppele R, Tolboom N, Yaqub M, Foster-Dingley JC, Windhorst AD, et al. Longitudinal amyloid imaging using 11C-PiB: methodologic considerations. J Nucl Med. 2013;54:1570\u20136. https:\/\/doi.org\/10.2967\/jnumed.112.113654.","journal-title":"J Nucl Med"},{"key":"5964_CR34","doi-asserted-by":"publisher","first-page":"440","DOI":"10.3389\/fnagi.2017.00440","volume":"9","author":"M Brendel","year":"2017","unstructured":"Brendel M, Schonecker S, Hoglinger G, Lindner S, Havla J, Blautzik J, et al. [(18)F]-THK5351 PET correlates with topology and symptom severity in progressive supranuclear palsy. Front Aging Neurosci. 2017;9:440. https:\/\/doi.org\/10.3389\/fnagi.2017.00440.","journal-title":"Front Aging Neurosci"},{"key":"5964_CR35","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/mds.27546","volume":"34","author":"JL Whitwell","year":"2019","unstructured":"Whitwell JL, Tosakulwong N, Schwarz CG, Botha H, Senjem ML, Spychalla AJ, et al. MRI outperforms [18F]AV-1451 PET as a longitudinal biomarker in progressive supranuclear palsy. Mov Disord. 2019;34:105\u201313. https:\/\/doi.org\/10.1002\/mds.27546.","journal-title":"Mov Disord"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-022-05964-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-022-05964-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-022-05964-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,8]],"date-time":"2023-01-08T23:04:04Z","timestamp":1673219044000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-022-05964-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,14]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["5964"],"URL":"https:\/\/doi.org\/10.1007\/s00259-022-05964-w","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,14]]},"assertion":[{"value":"17 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee (LMU Munich\u2014application number 17\u2013569) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Johannes Levin reports speaker fees from Bayer Vital, Biogen, and Roche; consulting fees from Axon Neuroscience and Biogen; author fees from Thieme medical publishers and W. Kohlhammer GmbH medical publishers; non-financial support from Abbvie; and compensation for duty as part-time CMO from MODAG, all outside the submitted work. Andrew W. Stephens is a full-time employee of Life Molecular Imaging, GmbH. Thilo van Eimeren reports speaker\/consultant fees from Eli Lilly, Shire, H. Lundbeck A\/S, and Orion Corporation and author fees from Thieme medical publishers, all without conflict of interest with regard to the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}